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Abstract. Human umbilical vein endothelial (HUVE)
cells have been previously reported to express the
genes for the A and B chains of PDGF and to secrete
PDGF-related factors into culture media. Antihuman
PDGF IgG affinity chromatography was used to purify
PDGF-related activity from HUVE cell-conditioned
media . Immunoblot analysis of the affinity-purified pro-
teins with anti-PDGF IgG and antibodies specific for
the A or B chain peptides of PDGF combined with
chemotactic and mitogenic assays revealed that the
major PDGF immunorelated molecule secreted by
HUVE cells is a monomer of ti 36-38 kD and that
T
HE vascular endothelium, which forms the nonthrom- Tbogenic bogenic lining of blood vessels, was once considered
a relatively inert membrane. Recent studies of endo-
thelial cells have demonstrated that they participate in nu-
merous structural and physiological functions of the circu-
latory system . Structural proteins including collagens and
laminin are secreted into the basement membrane, whilepro-
coagulant, anticoagulant, and platelet regulatory proteins
and growth regulatory molecules are secreted from the lumi-
nal membrane into the circulating blood or into a wound site
(Jaffe, 1984, 1987). Cultured endothelial cells have previ-
ously been shown to secrete factors that are chemotactic and
mitogenic for connective tissue cells. Approximately 30% of
this biological activity can be neutralized by antibodies spe-
cific for human PDGF (DiCorleto, 1984).
PDGF has been described as a mitoattractant due to its
chemotactic effect on connective tissue cellsat lowerconcen-
trations (0.1-1.0 nM) and its mitogenic effect on these cells
at higher concentrations (0.5-5 nM) (Grotendorst and Mar-
tin, 1986) . Because of the dual biological activity of this
molecule, PDGF is believed to be a major factor involved
in the normal healing of wounds and pathologically con-
tributing to the lesions of atherosclerosis, fibrotic diseases,
and oncogenesis. PDGF was originally identified (Ross et
al., 1974; Kohler and Lipton, 1974) and purified (An-
toniades et al., 1979; Heldin et al., 1981) from the alpha-
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<10% of the purified biologically active molecules are
PDGF A or B chain peptides. Screening of an HUVE
cell cDNA library in the expression vector lambda
gt11 with the anti-PDGF antibody resulted in the clon-
ing and sequencing of a cDNA with an open reading
frame encoding a 38-kD cysteine-rich secreted protein
which we show to be the major PDGF-related mitogen
secreted by human vascular endothelial cells. The pro-
tein has a 45% overall homology to the translation prod-
uct of the v-src-induced CEF-10 mRNA from chick
embryo fibroblasts. We have termed this new mitogen
connective tissue growth factor.
granules ofhumanplatelets. Platelet PDGF is a dimeric mol-
ecule that migrates on SDS-polyacrylamide gels at -30 kD.
Reduction of interchain disulfide bonds yields A chain (17
kD) and B chain (14 kD) monomers that are not biologically
active (Antoniades, 1981; Antoniades et al, 1979; Groten-
dorst et al ., 1982). Conditioned media from cultures of hu-
man umbilical vein endothelial (HUVE) cells contain factors
that compete with platelet PDGF for binding to the PDGF
cell surface receptor of fibroblasts and demonstrate PDGF-
related biological activity (DiCorleto, 1984). HUVE cells
express both the A and B chain genes of PDGF (Collins et
al ., 1985; Collins et al., 1987). Since both PDGF gene tran-
scripts are present, the exact nature of the proteins responsi-
ble for the PDGF-related mitoattractant activity found in
HUVE cell-conditioned media was uncertain . The secreted
molecules could be AB heterodimers or AA or BB homodi-
mers. All three isoforms have been purified from natural
sources and are biologically active (Heldin et al. 1986; Bet-
sholtz et al. 1986; Stoobant and Waterfield, 1984). Our ini-
tial interest was to determine the type of PDGF molecules
secreted by vascular endothelial cells. During the course of
these studies we have identified a new peptide that appears
to be responsible for the PDGF-related mitoattractant activ-
ity present in the endothelial cell-conditioned media. We
have termed this protein connective tissue growth factor
(C)GF). I
1. Abbreviations used in this paper: CTGF, connective tissue growth factor;
HUVE, human umbilical vein endothelial.Materials and Methods
Cells
HUVE cells were isolatedfrom fresh humanumbilical cords by collagenase
perfusion (Jaffe, 1987) and maintained in medium 199 with 20% FCS, 0.68
mM L-glutamine, 20 ug/ml Gentamicin, 90 pg/ml porcine heparin (Sigma
Chemical Co., St . Louis, MO), and 50 pg/ml endothelial cell growth sup-
plement (Sigma Chemical Co.) . Cells used for media collection were third
passage cells . Cells were identified as endothelial cells by their nonoverlap-
ping cobblestone morphology and by positive staining for factor-VIII
related antigen . NRKcellswere obtained fromAmericanType Culture Col-
lection (Rockville, MD), NIH/3T3 cells were a gift from S. Aaronson (Na-
tional Cancer Institute, Bethesda, MD), and both cell lines were maintained
in DMEM, 10% FCS, 20 Ag/ml Gentamicin . Fetal bovine aortic smooth
muscle cells were obtained from tissue explants as previously described
(Grotendorst et al ., 1981) and maintained inDMEM, 10% FCS, 20 Wg/ml
Gentamicin, and used in assays at second or third passage.
Growth Factors and Antibodies
HumanPDGF waspurified to homogeneity fromplatelets as describedpre-
viously (Grotendorst, 1984) . Recombinant AA, BB, and AB chain dimeric
PDGF molecules were obtained from Creative Biomolecules (Hopkinton,
MA) . FGF was obtained from Sigma Chemical Co. Purified PDGF or syn-
thetic peptides containing the amino and carboxyl sequences ofthe mature
PDGF A and B chain molecules were used to raise antibodies in goats .
Goats were immunized with 20 Rg ofpurified PDGF or 50 jig of synthetic
peptide in Freunds complete adjuvant by multiple intradermal injections.
Immune serawere collected 7 d after the fourth rechallenge (in Freunds in-
complete adjuvant) and subsequent rechallenges . The anti-PDGF antibody
did not show any cross-reactivity to TGF-ß, EGF, or FGF in immunoblot
analysis . The antipeptide antibodies were sequence specific and did not
cross-react with other synthetic peptide sequences or with recombinant
PDGF peptides that did not contain the specific antigenic sequence. This
was determined by Western blot and dot blot analysis .
Antibody Affinity Column
Goat anti-human PDGF IgG (150 mg) was covalently bound to 25 nil of
Affi-Gel 10 support (Bio-Rad Laboratories, Cambridge, MA) according to
the manufacturer's instructions with a final concentration of 6 mg IgG/ml
gel . The column was incubated with agitation at 4°C for 18 h with 1 liter
ofHUVE cell media that had been conditioned for 48 h . The gel was then
poured into a column (5 x 1 .5 cm), washed with 4 vol of 0 .1 N acetic acid
made pH 7.5 with ammonium acetate, and the antibody-bound PDGF
immunoreactive proteins were eluted with 1 N acetic acid . Peak fractions
were determined by biological assays and immunoblotting and the fractions
pooled .
Biological Assays
Chemotactic activity was determined in the Boyden chamber chemotaxis
assay with NIH 3T3 orbovine aortic smooth muscle (BASM) cells as previ-
ously described (Grotendorst et al ., 1981, 1987) . Mitogenic assays were
performed using 96-well plates and NRK fibroblasts or NIH 3T3 cells as
target cells . The cells are plated in DMEM, 10% FCS, and the NRK cell
cultures used 10-14 d after confluence and 3T3 cells made quiescent by in-
cubating for 2 d in serum-freeDMEM, 0.2 mg/ml BSA before use . Sample
proteins and dilutions ofknown standards were added to the wells and the
plates incubated at 37°C in 10% CO2, 90% air for 18 h, after which
3H-thymidine at a final concentration of5 ACi/ml was added and incubated
for an additional 2 h . The media was removed, the cells washed, and DNA
synthesis determined from the 3H-thymidine incorporation into TCA-pre-
cipitable material by scintillation counting .
Gel Electrophoresisand Immunoblotting
Electrophoresis was performed on 12% polyacrylamide gels containing
SDS (Laemntli, 1970) unless otherwise stated . Immunoblotting was per-
formed by electroblotting the proteins to anitrocellulose membrane and in-
cubating the membrane in 50mM Tris-HCI, pH 7.4, 100mM NaCl (TBS)
with 2% nonfatdry milk at25°C for 1 h to block nonspecific antibody bind-
ing. The blocking solution was removed and the antibody (15 jig/ml) added
in TBS containing 0.5 % nonfat dry milk and 1 wg/ml sodium azide and in-
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cubated overnight at 25'C . The membranes were then washed five times in
TBS, 0.5% milk for 10 min each wash and then incubated with alkaline
phosphatase-conjugated affinity purified rabbit anti-goat IgG (KPL, Gai-
thersburg, MA) at a 1:1,000 dilution in TBS containing 0.5% milk at 25°C
for 1 h . The filters were then washedwith TBS fivetimes, 10 min eachtime,
and the blot was developed using an alkaline phosphatase substrate solution
(0.1 M Tris-HCI, pH 9, 0.25 mg/ml nitro blue tetrazolium, 0.5 mg/ml
5-bromo-4-chloro-3-indolyl phosphate) .
Receptor Competition Assays
Assays were performed using confluent cultures of NIH 3T3 cells in 24-well
plates (Costar Data Packaging Corp., Cambridge, MA) grown in DMEM,
10% FSC, 10 pg/ml Gentamicin . The growth media was removed and the
cells were washed twice with serum-free DMEM, 0.2 mg/nil BSA, and the
plates placed on ice for 30 min in serum-free DMEM, 0.2 mg/ml BSA . Test
samples and controls were made up in serum-free DMEM, 0.2 mg/ml BSA
containing 5-10 ng/ml ofHUVE affinity-purified proteins and a serial dilu-
tion ofone ofthe recombinant PDGF isoforms in a concentration range of
300-16 ng/ml . 1-ml aliquots of the samples were placed into wells of the
24-well plates and incubated on ice on a platform rocker for 2 h . After the
incubation period, the cells were washed three times for 10 min each on
ice with PBS . The proteins bound to the surface of the cells were eluted
with 500 Al of 1 N acetic acid for 10 min . The acetic acid elution samples
were lyophilized, resuspended in 5 mM HCL, run on 12% polyacrylamide
gels, and immunoblotted to nitrocellulose using the anti-PDGF antibody.
RNA Isolation and Northern Blotting
Total RNA was isolated fromcells in monolayer culture cells by the method
of Chomczynski and Sacchi (1987) . Lyophilized RNA was resuspended in
gel loading buffer containing 50% formamide and heated at 95°C for2 min
before loading (20 jig per lane total RNA) onto 2 .2 M formaldehyde, 1%
agarose gels and run at 50 V. Integrity ofRNA was determined by ethidium
bromide staining and visualization of 18S and 28S rRNA bands . After elec-
trophoresis theRNA was transferred to nitrocellulose by blotting overnight
with IOx SSC . The nitrocellulose was air dried and baked at 80°C for 2 h
in a vacuum oven . Hybridization was performed overnight at 46°C with
the addition of 5 x 105 CPM per nil of 32p-labeled probe. Normally, for
Northern blots the entire plasmid was labeled and used as a probe. Labeling
was done with a random primer labeling kit from Boehringer Mannheim
Biochemicals (Indianapolis, IN) according to instructions provided . After
hybridization, membranes were washed twice in 2x SSC, 0.1% SDS for 15
min each at room temperature, once for 15 min in O.lx SSC, 0.1% SDS
room temperature, and a final 15-min washin O.lx SSC, 0.1% SDS at 46°C.
Blots were autoradiographed at 70°C on Kodak X-omat film.
Library Screening, Cloning, and Sequencing
Standard molecular biology techniques were used to subclone and purify
the various DNA clones (Sambrook et al ., 1989) . Clone DB60 was picked
from a lambda-gtlI HUVE cell cDNA library by induction of the fusion
proteins and screening with anti-PDGF antibody. Plaques picked were
rescreened and positive clones replated at low titer and isolated.
The EcoRI insertfromclone DB60 was cloned into the M13 phage vector
and single-stranded DNA obtained for clones with the insert in opposite
orientations. These M13 cloneswerethen sequenced by thedideoxy method
(Sanger, 1977) using the Sequenase kit (United States Biochemical Corp.,
Cleveland, OH) and 35S-dATP (duPont Co ., Wilmington, DE) . Both
strands ofDNA for this clone were completely sequenced using primer ex-
tension and both GTP and ITP chemistry. The sequencing reactions were
done according to the manufacturer's instructions . Aliquots of the sequenc-
ing reactions were run on both 6% acrylamide (16 h) and 8% acrylamide
(6 h) gels, vacuum dried, and autoradiographed for at least 18 h .
The cDNA fragment from clone DB60 was "P-CTP labeled and used
to rescreen theHUVE cell cDNA lambda gill library. Several clones were
picked and the largest, the 2,100-bp clone designated DB60R32, was sub-
cloned into Bluescript phagemid . Subclones were made of PstI, KpnI, and
EcoRI/KpnI restriction fragments, also in Bluescript. These subclones were
sequenced by double-stranded plasmid DNA sequencing techniques using
Sequenase as described above . The 1,458-bp EcoRI/KpnI clone containing
the open reading frame was subcloned into M13 mp18 and M13 mp19, and
both strands of DNA were completely sequenced using single-stranded
DNA sequencing techniques with primer extension and bothGTP and ITP
chemistry .
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In vitro transcription reactions were done using the 2,100-bp cDNA clone
DB60/32 in the Bluescript KS vector. The plasmid was cut with Xhol,
which cuts the plasmid once in the multiple cloning site of the vector 3' to
thecDNA insert . The T7 promoter site located 5' to thecDNA insert was
used for transcription. The in vitro transcriptions were done with a kit sup-
plied with the Bluescript vector by Stratagene Cloning Systems and the
manufacturer's instructions were followed.
In vitro translation reactions were done using nuclease-treated rabbit
reticulocyte lysate and 35S-cysteine in a cysteine-free amino acid mix for
labeling of the peptide . The reactions were done with a kit supplied from
Promega Biotec (Madison, WI) and the manufacturer's instructions were
followed . The reactions were done in a final volume of 50 ul containing
35S-,steine 1 mCi/ml (1,200 Ci/mMole, DuPont Co .), and serial dilutions
ofmRNA fromthe in vitrotranscription reactionsin concentrations ranging
from 50 to 500ng per reaction tube. The reactions were incubated at 30°C
for 60 min. Aliquots of the reactions were run reduced or nonreduced on
12% polyacrylamide electrophoresis gels, dried, and autoradiographed .
Bacterial expression of immunoreactive CTGF peptide was accom-
plished by subcloning clone DB60R32 into the EcoRI site ofthepET5 ex-
pression vector (Studier et al ., 1990) inboth sense and inverse orientations
(as determined by restriction enzyme digest analysis) . Cultures of cells were
grown inM9 media to anOD 600 of0.7 and the media made 0.4mM IPTG
and incubation continued for2 h . The cells were pelleted, lysed, inclusion
bodies removed by centrifugation, and aliquots of the pellet extracts run on
12% polyacrylamide gels and immunoblotted using the anti-PDGF an-
tibody.
For expression in Xenopus oocytes, mature X . laevis females were ob-
tained from Nasco (Fort Atkinson, WI) and maintained at room tempera-
ture . Frogs were anesthetized by hypothermia and the ovarian tissue was
surgically removed . Ovarian tissue was minced and digested the0.2% col-
lagenase (type 11 ; Sigma Chemical Co .) in OR-2 without calcium (Wallace
et al . 1973) for 2-3h . Unblemished stage VI oocytes (Dumont, 1972), 1.3-
mm diameter, were then carefully selected and microinjected .
Stage VI oocytes (5-10 at a time) were placed on a hollowed plexiglass
platform and drained of excess OR-2 solution . Approximately 50 nl of sam-
ple containing 10 ng ofRNA was injected into the animal pole just above
the oocyte equator using a Leitz system microinjector. After injection, oo-
cytes were returned to OR-2 buffer with 0.1% BSA and incubated for 24 h
at 25°C . Viable oocytes were then pooled and extracted by homogenization
in 100-mm NaCl, 10 mm Tris, pH 7.5, with ten strokes of a Dounce
homogenizer (20 pl/oocyte) . The homogenate was then mixed with an equal
volume of freon to remove pigment and lipid and centrifuged at 10,000 rpm
for 30 s to separate the phases . The top aqueous phase was removed and
tested for chemotactic activity using NIH 3T3 cells as described above .
Results
Identification and Partial Purification
ofPDGF-immunorelated MitogenfromHUVE Cells
Initial studies of the PDGF-related growth factors secreted
by HUVE cells were done by removing theserum-containing
growth media from confluent cultures of cells and replacing
it with serum-free media. Aliquots of this media were re-
movedperiodically and theproteins immunoblotted using an
antibody specific forhuman platelet PDGF (Fig . 1) . This an-
tibody does notcross-react with any otherknowngrowth fac-
tors and is able to detect <500 pg of dimeric PDGF or 10
ng of reduced, monomericAorBchainpeptide on immuno-
blots . The results indicated constitutive secretion of several
species of molecules which are immunologically similar to
platelet PDGF but are of higher relative molecular mass
(36-39 kD) than the expected 30-32 kD molecular mass of
platelet PDGF or A chain or B chain homodimers . Chemo-
tactic and mitogenic assays performed with this serum-free
conditioned media indicated the total biological activity
present was equivalent to 15 ng/ml of platelet PDGF after
a48-h conditioning period (Fig . 2) . Incubation of the media
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Figure 1 . Constitutive secre-
tion of PDGF-immunoreac-
tive factors by HUVE cells .
HUVE cells were grown to
confluence in 6-well plates .
The growth media was re-
moved, cells were washed
with PBS, and 1 ml of serum-
free media was added to each
well . The media was removed
after conditioning for the pe-
riod of time indicated (hours),
dialyzed against 1 N acetic
acid, and lyophilized . The samples were then runon 12% PAGE,
electroblotted to nitrocellulose, and visualized with theantihuman
PDGF antibody. 5 ng of purified platelet PDGF was run as refer-
ence . Positions of mol wt markers (Bio-Rad Laboratories) are in-
dicated at right .
with 30 Ag/ml of anti-human PDGF IgG neutralized
-20-30% of the mitogenic activity and similar amount of
the chemotactic activity . This is in agreement with previous
reports (DiCorleto, 1984) .
The presence in HUVE culture media of several species
of PDGF-immunoreactive molecules was unexpected, par-
ticularly moleculesof higher molecularweight than those of
theA andB chain dimeric molecules anticipated to be pro-
duced and secreted by endothelial cells (Collins et al ., 1987 ;
Sitaras et al ., 1987). To obtain greater amounts of the
PDGF-like proteins for further analysis, theHUVE cellshad
to be kept in media containing 20% FCS, as the cells begin
to die after 24 h in serum-free or low serum media . The
PDGF-immunoreactive proteins were partially purified from
the serum-containing media by use of an antibody affinity
column made with the anti-human PDGF IgG and an Afiï-
Gel 10 support (BioRad Laboratories) . When aliquots of the
partially purified proteins were assayed for chemotactic and
mitogenic activity, all biological activity could be neutral-
ized by prior incubation of the proteins with the antihuman
PDGF antibody (Fig . 2) . This indicated that theonly biolog-
ically active moleculespresent in the partially purified media
proteins were PDGF-immunorelated molecules . Aliquots of
the partially purified proteins were immunoblotted using the
same anti-PDGF antibody and the data indicated the pres-
ence of the higher molecular weight molecules observed in
the serum-free conditioned media (Fig . 3) . The major spe-
cies secreted migrates on polyacrylamide gels at 36 kD and
comprises at least 50% of the total immunoreactive pro-
tein purified from conditioned media . The immunoreactive
species migrating at 37 and 39 kD constitute most of the re-
maining immunoreactive protein . A similar pattern is seen
with proteins labeled with 35S-Cysteine and affinity purified
with the anti-PDGF IgG immunoafflnity column (data not
shown) . Less than 15% of the total affinity-purified proteins
comigrate with purified platelet PDGF or recombinant
PDGF isoforms . Prior incubation of the antibody with
purified PDGF (300 ng PDGF/2 Ag IgG) blocked antibody
binding to all of the molecules, indicating shared antigenic
determinants with dimeric platelet PDGF (Fig . 3, lane 4) . In-
terestingly, when the antibody was blocked with recom-
binant AA, BB, or AB dimers, antibody binding to the
HUVE-secreted proteins was inhibited equally by all three
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Figure 2 . Chemotactic and mitogenic assays of HUVE cell-con-
ditioned media and affinity-purified PDGF immunoreactive fac-
tors . (A) Mitogenic assay performed as described usingNRKcells
as target cells . PDGF BB is 5ng/ml . PDGFAA is 10 ng/ml . HUVE
media is 250 ul of HUVE cell serum-free conditioned media
(48 h) whichwas dialyzed against 1 N acetic acid, lyophilized, and
resuspended in DMEM before addition to test wells. Affinity-
purified fraction is 5 td/ml of combined, concentrated major pool
from Affe-Gel 10 affinity column. Anti-PDGF IgGor nonimmune
IgG(30,g/ml) wasadded to the samplesandincubated 18 h at 4°C
before testing in the mitogenic assay. Data points inA andBrepre-
sent the mean of triplicate samples and the standard deviation is
<5% . Theexperiments were repeatedat least three times with simi-
lar results. (B) Chemotactic assays were performed as described
under Materials and Methods using NIH 3T3 cells as target cells.
PDGF BB is 5 ng/ml . PDGF AA is 10 ng/ml . HUVE media is
serum-free DMEM, 0.2 mg/ml conditioned for 48 h . Affinity-
purified fraction is 2.5 pl/ml of combined, concentrated major pool
from Affi-Gel affinity column . Antibody neutralization is per-
formed as described under A .
dimeric forms, suggesting that the antibody recognizes com-
mon epitopes present on all three PDGF dimers and the
HUVE-secreted molecules (our unpublished observations) .
To insure that none of the antibody binding molecules de-
tected on Western blots were derived from FCS or otherad-
ditives in the culture media, a new, unused antibody affin-
ity column was made and media not conditioned by cells
was processed exactly as the conditioned media. No PDGF-
immunoreactive molecules were detected in the fractions
from this column by immunoblot (Fig . 3, lane 5) and no
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Figure 31mmunoblot ofHUVE
cell-secreted PDGF-related
factors . Proteins were run on
a 12% polyacrylamide gelelec-
troblotted to a nitrocellulose
membrane and theimmunore-
active factors visualized with
antihuman PDGF IgG as de-
scribed under Materials and
Methods. (lane 1) 5 ul of af-
finity-purified HUVE cell-se-
creted proteins . (lane2) 10 ng
of synthetic AA homodimer
(top band) and 10 ng of BB
homodimer(lowerband) . (lane
3) 50,ul of reduced HUVE affinity-purified proteins . (lane 4) 5 ul
ofHUVEaffinity-purifiedHUVE proteins but with antihumanPDGF
antibody blocked with 300 ng ofPDGF. (lane S) Controlcolumn of
1011 of anti-PDGF Affi-Gel 10 affinity-purified protein fraction
from media which was not conditioned by cells.
biological activity was detected (data not shown) . When
platelet PDGF or the recombinant dimers are reduced with
100mM DTT, monomericA chain (17 kD) and B chain (14
kD) peptides are observed on immunoblots . Treating the
HUVE molecules in a 100-mM DTT sample buffer results
in slower migration ofthe major immunoreactive peptides on
polyacrylamide gels (Fig . 3, lane 3) . Most of the immunore-
active molecules migrate at 38-39kD and less intensebands
are observed at 25 and 14 kD. It is necessary to run at least
10 times as much reduced protein as nonreduced in order to
detect the reduced molecules . This is consistent with the
affinity of our antibody for monomeric forms of the PDGF
A andB chain peptides . These data indicated that the major
species in the PDGF-related affinity-purified proteins from
conditioned media of HUVE cells was monomeric peptide
which migrates on acrylamide gels at an apparent molecular
mass of 36 kD nonreduced and 38 kD when reduced .
MajorChemotactic andMitogenic
Activity Is Produced by36-kDPeptideand Not
PDGF Peptides
To determine if thechemotactic and mitogenic activities ob-
served in the partially purified media proteins were from
molecules containing thePDGF A and B chain peptides or
were the products of molecules that do not contain these se-
quences, biological assays were performed with serial dilu-
tions of the affinity-purified media proteins and serial dilu-
tionsofrecombinantPDGF AA andBB homodimers and the
AB heterodimer. (Fig . 4) . Sufficient quantities of the sam-
ples were prepared to perform the mitogenic and chemotac-
tic assays andthe immunoblots with aliquots of each dilution
sample . Themitogenic activity oftheHUVE affinity-purified
factors observed was comparable to the activity elicited by
all three recombinant PDGF dimers . The chemotactic activ-
ity was comparable to the AB heterodimer, producing less
response than the BB homodimer and greater response than
theAA homodimer . When the biological activity ofthe sam-
ples wascompared with immunoblots ofequivalent amounts
ofthe same samples, noAchain norB chain molecules were
detected in the test samples (Fig . 4) . Thesedata demonstrate
the major biological activity present in theanti-PDGF affin-
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SFigure 4. Biological assays and immunoblots of serial dilutions of
HUVE cell affinity-purified media proteins and recombinant
PDGF standards . (A and B) Filled circle is HUVE cell affinity-
purified media proteins ; open circle is BB homodimer ; open trian-
gle is AB heterodimer ; closed triangle is AA homodimer. Mito-
genic assay (A) and chemotactic assay (B) were performed as
described with NIH 3T3 cells . The test samples in both biological
assays and the immunoblot are equal aliquots of the same dilution
sample . Data points represent the mean of triplicate samples with
SD <10% . (C) (immunoblot A) Primary antibody is anti-human
PDGF IgG . (lane 1) 20 ng HUVE purified media proteins . (lane
2) 20 ng AB heterodimer . (immunoblot B) Primary antibody is an-
tiamino terminalA chain serum . (lane 1) 20 ng of HUVE-purified
media proteins, reduced . (lane 2) 20 ngAA homodimer, reduced .
(lane 3) 1.25 ng AA homodimer, reduced . (immunoblot C) Pri-
mary antibody is anticarboxy terminal B chain serum . (lane 1) 20
ng HUVE-purified media proteins, reduced . (lane 2) 20 ng BB
homodimer, reduced . (lane 3) 2.5 ng BB homodimer, reduced .
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Figure 5 . PDGF cell surface receptor-binding competition assay
with NIH 3T3 cells andHUVE affinity-purified proteins competing
with recombinant PDGFBB homodimer. Lane 1 contains 10 ng of
HUVE affinity-purified proteins and lane 9 contains 1 .0 ng of
recombinant PDGF BB homodimer. Lanes 2-8 are proteins dis-
sociated in one well of a 24-well plate from the cell surface ofNIH
3T3 cells with acetic acid . The cells in each well were incubated
for 2 h at 4°C with serum-freeDMEM containing 10 ng ofaffinity-
purified protein from HUVE cell-conditioned media and varying
concentrations of recombinant PDGF BB . The concentration of
PDGF in lane 2 is 300 ng ; lane 3, 150 ng ; lane 4, 75 ng ; lane 5,
37.5 ng ; lane 6, 18.75 ng ; lane7, 9.4 ng ; and lane 8 contains no addi-
tion ofPDGF.
ity-purified fraction cannot be accounted for by PDGF A or
B chain-containing molecules and imply that the major
PDGF-immunoreactive protein species present in these sam-
ples (the 36-kD peptide) is biologically active and does not
contain amino acid sequences found in the amino and car-
boxy terminals of the PDGF A or B chain peptides .
To substantiate the binding of the endothelial cell mole-
cules to the PDGF cell surface receptors, competitive recep-
tor binding assays were performed . Because immunoblots of
the affinity-purified HUVE cell-secreted proteins indicated
the presence of multiple PDGF immunoreactive molecules,
1211-labeled PDGF competition assays could not be used
since this would not indicate which molecules in this mixture
were competing for binding of the labeled PDGF for the
receptors on the target cells . Since the isoforms ofPDGF and
the major PDGF immunorelated protein secreted by HUVE
cells are of different molecular weights, we were able to
demonstrate receptor binding competition on immunoblots .
Direct binding ofthe anti-PDGF immunoreactive peptides to
NIH 3T3 cells was demonstrated by incubating monolayers
of the 3T3 fibroblasts with the anti-PDGF affinity-purified
proteins (10 ng/ml) for 2 h at 4°C . Bound peptides were
released by washing of the cell layer with 1 N acetic acid and
quantitated by immunoblot analysis using anti-PDGF IgG
(Fig . 5) . The data show that the 36-kD immunoreactive
peptide binds to cell surface of NIH 3T3 cells . This binding
can be competed by increasing concentrations of recom-
binant PDGF BB added to the binding media . These data
suggest that the CTGF peptide binds to specific cell surface
receptors on NIH 3T3 cells and that PDGF BB can compete
with this binding . Whether CTGF binds to a certain class of
PDGF receptors or whether there is some cross reactivity of
PDGF BB with CTGF receptors that are distinct fromPDGF
receptors is not clear from these results and will require a
more in-depth study.
Cloning Expressionand Sequencing of thecDNA
for CTGF
To further characterize these PDGF-related molecules, we
1289Figure 6 . Northern blot of CTGF transcript in HUVE total RNA
and in vitro translation product ofcDNA clone DB60R32 and im-
munoreactive peptide from prokaryotic expression . (A)20 hg ofto-
talRNAfrom cultured HUVE cells was runon a 1.5% agarose gel,
transferred to nitrocellulose, and probed with 32plabeled DB60
clone . Autoradiograph indicates hybridization to a 2.4-kb tran-
script . (B) Lanes 1 and 2 are an immunoblot using the antihuman
PDGF antibody with (1) 10 ng nonreduced and(2) 100ng reduced
of HUVE cell affinity-purified proteins from conditioned media .
Lane 3 is an autoradiograph of 4 Al of a 50-,ul rabbit reticulocyte
in vitro translation reaction whichincorporated 1 Fig ofRNAtran-
script from an in vitro transcription reaction using the 2,100-bp
clone DB60R32 in Bluescript phagemid . Autoradiograph was ex-
posed for 24 h. (C) Clone DB60R32 was cloned into the EcoRl
site ofpET5 prokaryotic expression vectorin both senseand inverse
orientations. Protein expression was induced by IPTG for2 h and
20-,ul aliquots of cell pellet extract were run on 12% polyacryl-
amide gels andimmunoblotted using theanti-PDGFantibody. Lane
1 is the antisense control and lane 2 is the sense strand peptide pro-
duced by clone DB60R32 . (D) CappedmRNA was prepared by in
vitro transcription of the DB60R32 clone in Bluescript phagemid
after restriction with XhoI . Oocytes were microinjected with buffer
(control, noRNA) or 10 ug ofeither control orCTGF mRNA . To-
tal oocyte protein was extracted after 24 h. Chemotaxis assays were
performed as described under Materials and Methods with NIH
3T3 cells using25 p.g of oocyte total protein in each sample. PDGF
BB (5 ng/ml) positive control is shown for comparison . The results
represent the average of triplicate samples with a variation of<10% .
These studies were repeated twice .
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Figure 7 . Blocking of anti-
PDGF reactivity of native
CTGF by recombinant CTGF
produced in E . coli . Western
blots were performed using
CTGF isolated from endothe-
lial cell-conditioned mediaand
anti-PDGF IgG as described
under MaterialsandMethods .
Identical samples of CTGF
were probed with anti-PDGF
IgG that had been incubated
with control bacterial cell ex
tract (non-CTGF producing) (non-blocked) or with an equalamount
(50Wg total protein) of extract from arecombinant strain producing
CTGF (blocked) . These are thesame recombinant pETCTGF and
control bacterial cells used in the experiment described in Fig.
6 C . The recombinantCTGF completely blocked the immunoreac-
tivity oftheanti-PDGF with the nativeCTGF isolated from the con-
ditioned media .
first attempted to obtain sufficient quantities of the CTGF
protein for amino acid sequencing . However, the low con-
centrations ofCTGF in theconditioned media ofHUVE cell
cultures and the costly and time consuming techniques in-
volved in obtaining and culturing these cells made protein
purification to homogeneity and amino acid sequencing im-
practical . Therefore, we used the anti-PDGF antibody to
screen an HUVE cell cDNA library made in the expression
vector lambda gtl l (a gift from T . Collins, Harvard) . Over
500,000 recombinant clones were screened . Several clones
which gave strong signals with the anti-PDGF antibody in
the screening process were purified and subcloned into the
M13 phagevector and partial sequence data obtained by sin-
gle stranded DNA sequencing . A search of the GenBank
DNA sequence data base indicated that two of the clones
picked contained fragments of the PDGF B chain cDNA
open reading frame sequence . One of these clones was simi-
lar to a 1.8-kb insert previously isolated by Collins et al .
(1985) using a c-sis cDNA probe . A third clone of 500 by
was completely sequenced and no match was found in a ho-
mology search of all nucleotide and amino acid sequences
in GenBank (CEF 10 sequence was not available at that
time) . This clone was designated DB60 . Anti-PDGF anti-
body binding to the fusion protein produced by the clone
DB60 was completely blocked by the affinity-purified pro-
teins (not shown) . A "P-labeled probe was made of DB60
and used on a Northern blot of 20 hg of total RNA isolated
from HUVE cells (Fig . 6 A) . The blot indicated probe hy-
bridization with an mRNA of 2 .4 kb, which is a message of
sufficient size to producetheproteins in the38-kD molecular
mass range seen on the immunoblots of the affinity-purified
proteins . The DB60 clone was used to rescreen the HUVE
cell cDNA lambda gtl l library and the largest clone isolated
contained a 2,100-bp insert designated D1360R32 . A probe
made with the2,100-bpEcoRI insert of cloneDB60R32 also
hybridized with a single 2.4-kb message in a Northern blot
of total RNA from HUVE cells (not shown) . To determine
the size of the peptide encoded in the open reading frame of
DB60R32, the 2,100-bp insert was cloned into the Blue-
script vector and transcribed in vitro using T7 polymerase
and the mRNA transcript translated in vitro using a rabbit
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8. (A)Nucleotide sequence
and amino acid translation of
CTGF cDNA from humanvascu
lar endothelial cells. The open
readingframe forthe CTGF pro-
tein extends from the ATG initia-
tion site at nucleotide 130 to the
TGA site at 1177. The possible
glycosylation sites at asparagines
28 and 225 are underlined. The
putative alternative splicing re-
gion is boxed. The 3' region con-
tains three ATTTA sites which
are underlined. (B) Sequencing
map of CTGF cDNA clone. The
top line represents the 2,075-bp
DB60R32 clone containing the
open reading frameofCTGF. Re-
striction enzyme sites used in
subcloning are indicated as are
the ATG initiation site and the
TGA termination codon. Squares
indicate locationsof primersused
in sequencing. Solidarrows indi-
cate single-strandedDNAsequenc-
ing data and broken arrows indi-
cate area in 3' region sequenced
by double-strandedDNAmethods.reticulocyte lysate and 'SS-cysteine . Aliquots of the transla-
tion reaction were reduced with 50 mM DTT and run on
12% polyacrylamide gels . The data indicate a protein prod-
uct which migrates at an apparent molecular mass of 38 kD
and comigrates with the reduced affinity-purified proteins
observed on immunoblots (Fig . 6 B) . The clone DB60R32
was subcloned into the EcoRI site ofthe prokaryotic expres-
sion vector pET 5 in both orientations and transfected into
E. coli strain HMS174 . The CTGF protein was induced by
IPTG and aliquots of the cell lysate were immunoblotted
(Fig . 6 C) . The protein produced by clone DB60R32 in the
sense orientation produced anti-PDGF immunoreactive pep-
tides in the 36-39 kD molecular mass range, while the anti-
sense control produced no immunoreactive peptides . The
recombinant peptides produced in the E. coli system com-
pletely blocked the anti-PDGF reaction with the CTGF pep-
tides present in conditioned media (Fig . 7) .
Bioassays ofextracts of the recombinant bacterial cells that
were producing the CTGF peptide were negative. We then
evaluated several eukaryotic expression systems, including
microinjection of Xenopus oocytes . Injection of Xenopus
oocytes with 10 ng of RNA preparations derived by in vitro
transcription of the DB60R32 clone resulted in the produc-
tion of a fibroblast chemotactic activity . (Fig . 6 D) . Control
injected cells did not produce this activity. These results in-
dicate that the open reading frame of theDB60R32 clone en-
codes a protein with chemotactic activity for fibroblastic
cells as does CTGF.
The 2,100-bp insert of cloneDB60R32 was sequenced ini-
tially by subcloning of Pst I and KpnI restriction fragments
into Bluescript and using double-stranded dideoxy methods .
This determined an open reading frame of 1,047 base pairs
and oriented the DB60 insert to the larger cDNA (Fig . 8) .
An EcoR1/KpnI fragment containing the entire open reading
frame was inserted into Ml 3 mp18 and M13 mp19, and both
strands of the DNA were sequenced with single-stranded
dideoxy methods by primer extension using both GTP and
the GTP analogue ITP. The cDNA nucleotide sequence of
the open reading frame encoded a 38,000 mol wt protein,
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Figure 9 Comparison of ami-
no acid sequences ofthe trans-
lated cDNA for CTGF and
the CEF-10mRNA translation
product . ThetranslatedcDNA
for human CTGF and avian
CEF-10 have a 45% overall
homology and a 52% homol-
ogy if the putative alternative
splicing region is deleted . This
region is between amino acids
171 (aspartic acid) and 199
(cysteine) in the CTGF se-
quence . Homologous regions
are shaded and the aligned
cysteines are marked with an
asterisk .
confirming our cell-free translation results and matching the
size of the immunopurified peptides (Fig . 8) . A new search
of the GenBank data base revealed that this cDNA had a 50
nucleotide sequence homology with CEF-10mRNA, one of
the immediate early genes induced in v-src-transformed
chicken embryo fibroblasts (Simons et al ., 1989) (Fig . 9) .
Discussion
The data presented here indicate that the major connective
tissue mitoattractant secreted by HUVE cells is a 38-kD
monomeric molecule which appears to be antigenically and
functionally related to PDGF, but is not a product of the
PDGF A or B chain genes . We find that HUVE cells also
secrete both PDGF A and B chain molecules, but at much
lower concentrations than the 38-kD monomer and these
peptides contribute only a minor fraction (<10%) of the total
PDGF-related chemotactic and mitogenic activity secreted
by these cells under the conditions tested . In the biological
assays performed with the affinity-purified proteins from
HUVE media, biological activity equivalent to 20 ng/ml of
PDGF was obtained at low concentrations of the CTGF mol-
ecule where no detectable (<2 ng) PDGF A orB chain mole-
cules were present . All biological activity could be removed
by prior incubation of these samples with the anti-PDGF an-
tibody. Because all three isomeric forms of the PDGF dimers
blocked antibody binding to the CTGF molecule, it is sug-
gested that there are some common antigenic determinants
shared among these proteins although there is little if any
peptide sequence homology. The anti-PDGF antibody has
high affinity to the nonreduced forms of the PDGF isomers
and the CTGF molecule and tenfold less affinity to the re-
duced forms of these peptides which lack biologically activ-
ity. This suggests that there are regions of shared tertiary
structure between the PDGF isomers and the CTGF mole-
cule, resulting in common antigenic epitopes and possible
receptor binding sites of these molecules .
The sequence of the cDNA for CTGF indicates an open
reading frame of 1,047 nucleotides with an initiation site at
1292position 130 and a TGA termination site at position 1,177
which encodes a peptide of 349 amino acids (Fig. 8) . The
ATG codon at position 130 and another at position 145 fit
the consensus sequence for strong translation initiation sites
(Kozak, 1984) and it is assumed that the first ATG is the pre-
dominant initiation site. There is a 40% sequence homology
between the CTGF cDNA and the cDNA for both the A and
B chains of PDGF, suggesting a possible common ancestral
gene. The 3' region contains three copies of the pentanucleo-
tide sequence ATTTA shown to be involved in mRNA
destabilization and frequently found in cytokine and on-
cogene mRNA 3' regions (Shaw and Kamen, 1986) .
The CTGF open reading frame encodes a peptide that con-
tains 39 cysteine residues, indicating a protein of complex
structure with multiple intramolecular disulfide bonds. This
may explain the shift to slower mobility observed on poly-
acrylamide gels after reduction of the molecule with DTT.
The amino terminal of the peptide contains a hydrophobic
signal sequence indicative of a secreted protein, and there
are two N-linked glycosylation sites at asparagine residues
28 and 225 in the amino acid sequence. There is a 45 % over-
all sequence homology between the CTGF peptide and the
protein encoded by the CEF-10 mRNA transcript and the ho-
mology rises to 52% when a putative alternative splicing re-
gion is deleted . All 39 cysteine residues in each peptide can
be aligned with few gaps in the sequences (Fig . 9). The re-
gion between amino acid residues 171 (aspartic acid) and
199 (cysteine) in the CTGF peptide has no significant homol-
ogy to the corresponding region in the CEF-10 sequence
(amino acids 168-224) and is 28 amino acids shorter. This
discrepancy couldbe due to differences incurred during evo-
lution of the chicken and human genes. However, because
this region is bordered by areas of very high homology be-
tween the two molecules (>85 % identity) it may indicate al-
ternative splicing mechanisms in the expression of this gene.
The codons for lysine at residue 170 and aspartic acid at resi-
due 171 together form the AAG/G sequence consistent with
a 3' exon/5' exon junction . Alternative splicing is found in
other growth factor transcripts such as the PDGF A chain
(Collins et al ., 1987) and vascular endothelial growth factor
(Leung et al ., 1989; Keck et al ., 1989 ; Tischer et al ., 1989).
The biological significance of either of these splicing events
has not yet been determined.
Simmons et al . (1989) cloned the CEF-10 mRNA, which
was one of 12 identified cDNA sequences transcribed from
mRNAs that were induced soon after the production of the
src phosphoprotein pp60,-s« in chicken embryo fibroblasts.
The CEF-10 mRNA was induced in nontransfected CEF
cells by serum. Both the src protein and serum induce the
expression of the "immediate early genes" many ofwhich are
necessary for the Go-G, transition in the cell cycle (for re-
view see Rollins and Stiles, 1989) . One major group ofthese
genes consists of intranuclear DNA-binding proteins includ-
ing fos, myc, andjun, which are essential for cell cycle regu-
lation . Another major group of genes induced by serum and
src encodes secretory proteins with cytokine characteristics
such as the JC gene (Cochran et al ., 1983), which has a
cDNA sequence with significant homology to the cytokines
macrophage colony stimulating factor (M-CSF), alphainter-
feron and interlukin-2 (Rollins et al., 1988), or the KC gene
(Cochran et al ., 1983) which is homologous to the gro gene
in humans (Oquendo et al., 1989 ; Anisowicz et al., 1987) .
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The gro protein product is related to CEF-4, another of the
12 src and serum-inducible mRNAs cloned from CEF cells
(Bedard et al ., 1987) . We have found that the CTGF gene
is rapidly induced by serum in human skin fibroblasts and
that cycloheximide treatment does not block this induction
(Igarashi, A., and G. R. Grotendorst, manuscript submitted
for publication). Thus, the CTGF gene is an immediate early
gene which appears to encode a secreted peptide with cyto-
kine activity.
The data presented here suggest that the CTGF molecule
has biological activity similar to PDGF and may bind one
of the PDGF cell surface receptors. CTGF couldfunction in
many biological processes involving the growth of connec-
tive tissue. The fact that we find CTGF secreted by vascular
endothelial cells indicates that the peptide could be present
in serum . The conditions under which the protein would be
secreted in vivo are not yet known and we are currently pur-
suing studies on the regulation of gene expression and pro-
tein secretion by cultured endothelial cells. Secretion of
CTGF during angiogenesis would facilitate the growth of
smooth muscle cellsand fibroblasts so that it may play an im-
portant role in the control of blood vessel formation during
development and wound repair. CTGF couldalso play a role
in atherosclerosis where it could function to recruit smooth
muscle cells from the medial layer of the vessel wall into the
intima. Other investigators have detected PDGF transcripts
in arterial tissues (Barrett and Benditt, 1987), and the PDGF
mRNA levels appear to be elevated in atherosclerotic lesions
(Barrett and Benditt, 1988). The secretion ofCTGF peptides
by endothelial cells would also stimulate the chemotaxis and
growth of smooth muscle and fibroblasts at the plaque site,
thereby aggravating vessel blockage. Whether CTGF pro-
duction is required for transformation by the src oncogene
remains to be determined, but it is interesting that CTGF
could function as an autocrine growth factor for src trans-
formed fibroblasts. Direct experiments to determine the
transforming potential of this cDNA are currently underway.
We are also in the process ofconstructing vectors for eukary-
otic expression systems in order to obtain recombinant
CTGF for further analysis. Future experiments using CTGF-
specific antibodies and nucleotide probes should help to de-
termine the role of CTGF during the normal biological and
pathological processes which involve connective tissue for-
mation .
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